Olema Q1 2025: $392.7M cash, net loss $30.4M; palazestrant combo mPFS 13.8 months

Olema Pharmaceuticals, Inc.

2025-Q1 EPS reported -$0.36

Cash, cash equivalents, and marketable securities of $392.7M at March 31, 2025; net loss $30.4M.
Updated mPFS from Phase 1b/2: 13.8 months (all patients) and 13.1 months (prior CDK4/6i) for palazestrant+ribociclib.
Phase 3 OPERA-01 top-line data expected in 2026; OPERA-02 in frontline breast cancer to start in 2025.
GAAP R&D expenses $30.6M in Q1 2025, up from $29.9M; non-GAAP R&D $27.3M excluding stock comp.
OP-3136 Phase 1 trial enrollment ongoing; preclinical data at AACR showed activity in ovarian, NSCLC, prostate.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.